Hsbc Holdings PLC Has $509.45 Million Position in Abbott Laboratories $ABT

Posted by Brian Himes on Jun 20th, 2026

Hsbc Holdings PLC boosted its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 5.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,063,870 shares of the healthcare product maker’s stock after acquiring an additional 206,834 shares during the period. Hsbc Holdings PLC’s holdings in Abbott Laboratories were worth $509,448,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Freemont Management S.A. increased its position in Abbott Laboratories by 197.2% during the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after buying an additional 7,100 shares during the period. PFA Pension Forsikringsaktieselskab bought a new stake in shares of Abbott Laboratories in the fourth quarter valued at about $116,580,000. Thrivent Financial for Lutherans boosted its position in shares of Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after acquiring an additional 48,286 shares during the period. Danica Pension Livsforsikringsaktieselskab acquired a new position in shares of Abbott Laboratories in the third quarter valued at about $185,640,000. Finally, Net Worth Advisory Group bought a new position in Abbott Laboratories during the fourth quarter worth about $1,366,000. 75.18% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was acquired at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Philip P. Boudreau bought 2,200 shares of the business’s stock in a transaction on Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $88.48 on Friday. The business has a fifty day simple moving average of $90.08 and a 200 day simple moving average of $106.60. The company has a market cap of $154.12 billion, a P/E ratio of 24.78, a P/E/G ratio of 1.52 and a beta of 0.63. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.8%. Abbott Laboratories’s payout ratio is 70.59%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ABT shares. Argus cut their price objective on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, April 21st. Mizuho lowered their target price on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Bank of America dropped their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Evercore reduced their price target on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Finally, Benchmark lowered their price objective on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.30.

Read Our Latest Report on ABT

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.